The $11 million Series B round was closed by Guard Medical Inc., a Miami-based developer of solutions to prophylactic Negative Pressure Wound Therapy, (NPWT), wound care for closed surgical incisions.
Current investors include Bpifrance and Matignon Investissement et Gestion.
Guard Medical CEO Machiel Van der Leest is responsible for developing solutions to prophylactic Negative Pressure Wound therapy (NPWT) that can be applied to a wide variety of surgical injuries. These include scar mitigation, infection prevention and enhancements in cosmesis. Its NPWT technology originated with New York-Presbyterian and Weill Cornell Medicine in response to physician’s identification of unmet needs related to Surgical Site Infections (SSI).
The capital will support commercialization and clinical studies of its (NPWT) dressing NPsealTM for the treatment of closed surgical incisions. NPsealTM is an easy-to-use and cost-effective NPWT surgical dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.